EGFR and non-small cell lung carcinoma: EGFR19-del and 21L858R mutations increase the risk of VPI.[18] EGFR-TKIs targeting[19,20] is the recommended standard of care for patients with advanced EGFR-mutated NSCLC, and recommendations state that all NSCLC patients should have EGFR mutation testing performed at initial diagnosis.[16] More than 200 types of EGFR mutations have been detected, among which there are differences in clinical characteristics, prognosis, and sensitivity to EGFR-TKIs among different mutation subtypes.